Stockreport

Regeneron beats quarterly profit estimates on Dupixent strength [Yahoo! Finance Canada]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Dupixent, which Regeneron co-develops with French drugmaker Sanofi, has ?become an increasingly important growth driver as sales of its eye disease drug, Eylea, faces ? [Read more]